You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
SBC: Sarya, LLC Topic: 102PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
SBC: IMMUNOPHOTONICS INC Topic: 102Abstract: Immunophotonics is a biotech company developing a synthetic biopolymer, IP-001, to potentiate a systemic immunotherapy via microwave (MWA) thermal tumor ablation for treatment of Hepatocellular carcinoma (HCC). The goal of this SBIR Fast Track is to complete preclinical safety and efficacy testing to support an investigational new drug (IND) application based on the feedback from a meeti ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIAAge-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a wearable light-based remote monitoring system for early detection of postpartum hemorrhage
SBC: ARMOR MEDICAL INC. Topic: CDCPROJECT SUMMARY There is an urgent need to develop technologies which address preventable causes of maternal deaths and improve maternal health outcomes. In the United States (US) there exist deeply concerning racial and ethnic disparities in maternal health outcomes (with black mothers experiencing a rt3x higher mortality rate than non- black mothers). Furthermore, the US has the highest maternal ...
SBIR Phase I 2023 Department of Health and Human ServicesCenters for Disease Control and Prevention -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SBIR Phase I:Directed evolution of site-specific bacterial transposase genes to alter specificity and efficiency of insertion of large DNA segments into restorable gene fusions
SBC: SYNTHETIC VECTOR DESIGNS, LLC Topic: BTThe broader impact of this Small Business Innovation Research (SBIR) Phase I project will be to develop methods to facilitate the efficient, reproducible insertion of large DNA segments into stable locations on bacterial vectors, viral and non-viral shuttle vectors, and the chromosomes of prokaryotic and eukaryotic host cells comprising novel target sequences plus helper and donor vectors that cou ...
SBIR Phase I 2023 National Science Foundation -
Targeting LRRC8 signaling to prevent and treat arterial thrombosis in type 2 diabetes
SBC: Senseion Therapeutics, Inc. Topic: NHLBIProject SummaryCardiovascular disease (CVD) including stroke and myocardial infarction (MI), and Type 2 diabetes (T2D) areoverlapping global pandemics. CVD is the most common cause of death in patients with T2D and the economicburden of stroke and myocardial ischemia in patients with T2D is staggering. While newer glycemic controlagents like SGLT2 inhibitors and GLP1 agonists can help reduce CVD e ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
AI Cross-validation of IoT systems to increase Accuracy, Trust, and Mission Readiness
SBC: THERMOAI INC Topic: X224OCSO1Leveraging advanced cyber-physical systems (CPS) and clustering machine learning can crosscheck signal in Air Force Internet of Things (IoT) systems that control critical infrastructure, autonomous vehicles, and C4ISR control systems- increasing accuracy,
SBIR Phase II 2023 Department of DefenseAir Force -
GW-TT2, a New Drug Product for Tinnitus.
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: PA19272Every soldier, Marine, airman, and sailor will be exposed to hazardous noise at some point in his or her career. One major consequence of noise exposure is tinnitus. Tinnitus can impede communication, reduce environmental and social awareness, and degrade combat performance and mission effectiveness. Tinnitus can also harm a service member’s quality of life and future employability with severe f ...
SBIR Phase II 2023 Department of DefenseDefense Health Agency -
A Platform to Identify Antifungal Compounds with Novel Action Mechanisms
SBC: INTACT GENOMICS INC Topic: R43Project Summary There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. Antifungal compound discovery has been forgotten or neglected (see a review publication 2021 at Research Strategy). One of the best possible sources for new antifungal compounds with potentially novel mechanisms of action i ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health